BRCA1 and BRCA2 in breast cancer

By Yang X.   Lippman M.E.  

Breast Cancer Research and Treatment, Vol. 54, Iss. 1, 1999-03 ,pp. : 1-10

Springer Publishing Company

Access to resources Recommend Favorite

BRCA1 protein levels and PIK3CA mutations as predictive biomarkers for response to neoadjuvant chemotherapy in locally advanced breast cancer: An exploratory analysis

By                        

Oncology Letters, Vol. 4, Iss. 1, 2012-01 ,pp. : 141-145

Spandidos Publications

Access to resources Recommend Favorite

BRCA-1 methylation and TP53 mutation in triple-negative breast cancer patients without pathological complete response to taxane-based neoadjuvant chemotherapy

By Foedermayr Mathilde   Sebesta Miriam   Rudas Margaretha   Berghoff Anna   Promberger Regina   Preusser Matthias   Dubsky Peter   Fitzal Florian   Gnant Michael   Steger Guenther   Weltermann Ansgar   Zielinski Christoph   Zach Otto   Bartsch Rupert  

Cancer Chemotherapy and Pharmacology, Vol. 73, Iss. 4, 2014-04 ,pp. : 771-778

Springer Publishing Company

Access to resources Recommend Favorite

Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer

By Reding Kerryn  

Breast Cancer Research and Treatment, Vol. 123, Iss. 2, 2010-09 ,pp. : 491-498

Springer Publishing Company

Access to resources Recommend Favorite

Predictors of pathological complete response to neoadjuvant chemotherapy in stage II and III breast cancer: The impact of chemotherapeutic regimen

By        

Molecular and Clinical Oncology, Vol. 3, Iss. 5, 2015-01 ,pp. : 1117-1122

Science Publishers

Access to resources Recommend Favorite